Caladrius Biosciences to Present on CLBS119 for COVID-19 Induced Lung Damage at the BioNJ COVID-19 Rapid Fire Research Showcase

BASKING RIDGE, N.J. (June 2, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease today announced that the company has been selected to present at the BioNJ COVID-19 Rapid Fire Research Showcase on Friday, June 5, 2020. David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius Biosciences, will present an overview of CLBS119, Caladrius’ CD34+ cell therapy product candidate targeting repair of COVID-19 induced lung damage. For more information on BioNJ’s COVID-19 Rapid Fire Research Showcase, please click here . About Caladrius Biosciences Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are developing a first- in-class cell therapy product that is based on the notion that our body contains finely tuned mechanisms for self-repair. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. The Company’s current product candidates include CLBS119, a CD34+ cell therapy product candidate for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, for which the Company plans to initiate a clinical trial in the coming months as well as three developmental treatments for ischemic diseases based on its CD34+ cell therapy platform: CLBS12, recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; CLBS16, the subject of a recently completed positive Phase 2 clinical trial in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); and CLBS14, a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”). For more information on the company, please visit www.caladrius.com . Contact: Investors: Caladrius Biosciences, Inc. John Menditto Vice President, Investor Relations and Corporate Communications Phone: +1-908-842-0084 Email: [email protected] Media: W2O Group Christiana Pascale Phone: +1-212-257-6722 Email: [email protected] Source: Caladrius Biosciences, Inc. Print Page RSS Feeds Email Alerts Caladrius Caladrius About Us Overview Management Team Board of Directors Pipeline Overview Advanced Solid Tumors Certepetide (LSTA1) Research & Technology Overview CendR Platform® Technology – Targeted penetration technology to enhance drug delivery to advanced solid tumors CD34+ Cell Technology Publications Investors & News Overview News & Events Financials & Filings Stock Information Corporate Governance Historical Information Investor Resources Patients & Families Overview Cholangiocarcinoma (Bile Duct Cancer) Signs, Symptoms and Treatment Metastatic Pancreatic Ductal Adenocarcinoma Symptoms, Signs & Treatment Clinical Trials Facebook Twitter LinkedIn Join Our Email List 110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920 | Telephone 908.842.0100 © 2026 Lisata Therapeutics, Inc. All rights reserved. Site Map Privacy Policy 110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920 | Telephone 908.842.0100

The release as fetched from its publisher. lisata.com ↗